Search Page

1

Cite

Share

Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference.

Llovet JM, Villanueva A, Marrero JA, Schwartz M, Meyer T, Galle PR, Lencioni R, Greten TF, Kudo M, Mandrekar SJ, Zhu AX, Finn RS, Roberts LR; AASLD Panel of Experts on Trial Design in HCC. Llovet JM, et al. Hepatology. 2021 Jan;73 Suppl 1:158-191. doi: 10.1002/hep.31327. Epub 2020 Sep 9. Hepatology. 2021. PMID: 32430997 Review. No abstract available.

Cite

Share

2

Cite

Share

Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference^‡.

Cornberg M, Lok AS, Terrault NA, Zoulim F; 2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Cornberg M, et al. J Hepatol. 2020 Mar;72(3):539-557. doi: 10.1016/j.jhep.2019.11.003. Epub 2019 Nov 12. J Hepatol. 2020. PMID: 31730789 Free article. Review.

Cite

Share

3

Cite

Share

Management of adult patients with ascites due to cirrhosis: an update.

Runyon BA; AASLD Practice Guidelines Committee. Runyon BA, et al. Hepatology. 2009 Jun;49(6):2087-107. doi: 10.1002/hep.22853. Hepatology. 2009. PMID: 19475696 No abstract available.

Cite

Share

4

Cite

Share

Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.

Ghany MG, Morgan TR; AASLD-IDSA Hepatitis C Guidance Panel. Ghany MG, et al. Hepatology. 2020 Feb;71(2):686-721. doi: 10.1002/hep.31060. Hepatology. 2020. PMID: 31816111 No abstract available.

Cite

Share

5

Cite

Share

Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.

AASLD-IDSA HCV Guidance Panel. AASLD-IDSA HCV Guidance Panel. Clin Infect Dis. 2018 Oct 30;67(10):1477-1492. doi: 10.1093/cid/ciy585. Clin Infect Dis. 2018. PMID: 30215672 Free PMC article.

Cite

Share

6

Cite

Share

Reply.

Chalasani N; Writing Group for the AASLD NAFLD Practice Gudiance. Chalasani N, et al. Hepatology. 2018 Jun;67(6):2478-2479. doi: 10.1002/hep.29841. Epub 2018 Apr 26. Hepatology. 2018. PMID: 29443382 No abstract available.

Cite

Share

7

Cite

Share

Diagnosis and treatment of Wilson disease: an update.

Roberts EA, Schilsky ML; American Association for Study of Liver Diseases (AASLD). Roberts EA, et al. Hepatology. 2008 Jun;47(6):2089-111. doi: 10.1002/hep.22261. Hepatology. 2008. PMID: 18506894 No abstract available.

Cite

Share

8

Cite

Share

Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012.

Runyon BA; AASLD. Runyon BA, et al. Hepatology. 2013 Apr;57(4):1651-3. doi: 10.1002/hep.26359. Hepatology. 2013. PMID: 23463403 No abstract available.

Cite

Share

9

Cite

Share

Reply.

Aronsohn AI, Bhattacharya D, Morgan TR, Wyles DL, Chung RT, McQuillen DP; AASLD-IDSA HCV Guidance. Aronsohn AI, et al. Hepatology. 2022 Apr;75(4):1055-1056. doi: 10.1002/hep.32257. Epub 2021 Dec 19. Hepatology. 2022. PMID: 34859470 No abstract available.

Cite

Share

10

Cite

Share

American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease.

Fix OK, Blumberg EA, Chang KM, Chu J, Chung RT, Goacher EK, Hameed B, Kaul DR, Kulik LM, Kwok RM, McGuire BM, Mulligan DC, Price JC, Reau NS, Reddy KR, Reynolds A, Rosen HR, Russo MW, Schilsky ML, Verna EC, Ward JW, Fontana RJ; AASLD COVID-19 Vaccine Working Group. Fix OK, et al. Hepatology. 2021 Aug;74(2):1049-1064. doi: 10.1002/hep.31751. Hepatology. 2021. PMID: 33577086 Free PMC article.

Cite

Share